Table 4 Most significant pathways enriched with top 1% genes associated with WMH. Two genes, IL4R and CD79A were highlighted as they both reached the significance cutoff WMH (FDRÂ <Â 0.05)
From: Whole blood gene expression and white matter Hyperintensities
Biological pathway | Total number of genes in the pathway | Ratio of enrichment | P value | FDR | Top 1% genes associated with WMH |
|---|---|---|---|---|---|
Hematopoietic cell lineage | 97 | 7.99 | 6.0E-06 | 0.0018 | HLA-DOB; HLA-DRA; IL4R; IL5RA; CD8A; CD19; CD22; CD37 |
Antigen processing and presentation | 77 | 8.81 | 1.3E-05 | 0.0019 | PSME3; HLA-DOB; HLA-DRA; KLRC3; KLRD1; CIITA; CD8A |
Inflammatory bowel disease (IBD) | 65 | 8.95 | 5.0E-05 | 0.0050 | HLA-DOB; HLA-DRA; IL4R; RORA; STAT4; IL18R1 |
Primary immunodeficiency | 37 | 10.48 | 5.3E-04 | 0.0338 | CIITA; CD8A; CD19; CD79A |
Apoptosis | 140 | 4.85 | 5.6E-04 | 0.0338 | BCL2L11; TUBA1B; CTSW; GZMB; BIRC3; TNFRSF10C; MAP3K14 |
Graft-versus-host disease | 41 | 9.46 | 7.9E-04 | 0.0399 | GZMB; HLA-DOB; HLA-DRA; KLRD1 |
Cytokine-cytokine receptor interaction | 265 | 2.93 | 0.005668 | 0.231 | CCR7; IL4R; IL5RA; PDGFRB; CCL4; CXCR5; TNFRSF10C; IL18R1 |
B cell receptor signaling pathway | 73 | 5.3 | 0.006633 | 0.231 | CD19; CD22; CD72; CD79A |
Allograft rejection | 38 | 7.7 | 0.006858 | 0.231 | GZMB; HLA-DOB; HLA-DRA |
Type I diabetes mellitus | 43 | 6.8 | 0.009672 | 0.285 | GZMB; HLA-DOB; HLA-DRA |